Review of the safety and efficacy of ustekinumab | Zendy

Ellen Scherl | Zendy; Sheila Kumar | Zendy; Ryan Warren | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Review of the safety and efficacy of ustekinumab

Author(s) -

Ellen Scherl,

Sheila Kumar,

Ryan Warren

Publication year - 2010

Publication title -

therapeutic advances in gastroenterology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.278

H-Index - 51

eISSN - 1756-2848

pISSN - 1756-283X

DOI - 10.1177/1756283x10374216

Subject(s) - ustekinumab , medicine , interleukin 23 , infliximab , psoriasis , crohn's disease , inflammatory bowel disease , immunology , monoclonal antibody , clinical trial , multiple sclerosis , disease , immune system , antibody , interleukin 17

Ustekinumab is a subcutaneously and intravenously administered fully human monoclonal immunoglobulin (IgG1) antibody targeting the interleukin (IL)-12/23 shared P40 subunit. The pivotal role of IL-12/23 inflammatory-mediated pathways is increasingly recognized in a plethora of immune-mediated inflammatory disorders including Crohn's disease, psoriasis, and multiple sclerosis. In a randomized controlled trial of ustekinumab in moderate-to-severe Crohn's disease, clinical response was achieved most notably in infliximab-experienced primary and secondary nonresponders and suboptimal responders.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research